The DOI matches its Crossref record; 237 of the 237 references it cites were found in a registry or an index.
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Open accessAbstract
Since cloning of the ATP-binding cassette (ABC) family member breast cancer resistance protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter in 1998, BCRP has been the subject of more than two thousand scholarly articles. In normal tissues, BCRP functions as a defense mechanism against toxins and xenobiotics, with expression in the gut, bile canaliculi, placenta, blood-testis and blood-brain barriers facilitating excretion and limiting absorption of potentially toxic substrate molecules, including many cancer chemotherapeutic drugs. BCRP also plays a key role in heme and folate homeostasis, which may help normal cells survive under conditions of hypoxia. BCRP expression appears to be a characteristic of certain normal tissue stem cells termed “side population cells,” which are identified on flow cytometric analysis by their ability to exclude Hoechst 33342, a BCRP substrate fluorescent dye. Hence, BCRP expression may contribute to the natural resistance and longevity of these normal stem cells. Malignant tissues can exploit the properties of BCRP to survive hypoxia and to evade exposure to chemotherapeutic drugs. Evidence is mounting that many cancers display subpopulations of stem cells that are responsible for tumor self-renewal. Such stem cells frequently manifest the “side population” phenotype characterized by expression of BCRP and other ABC transporters. Along with other factors, these transporters may contribute to the inherent resistance of these neoplasms and their failure to be cured.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–237 of 237
Mosaffa, F., Lage, H., Afshari, J. T., & Behravan, J. (2009) · Inflammation Research · doi:10.1007/s00011-009-0034-6 · Cited by 50
Impact of Breast Cancer Resistance Protein on Cancer Treatment Outcomes
Ross, D. D., & Nakanishi, T. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_12 · Cited by 49
Self-citationThe role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert, S. L. A., van der Kolk, D. M., de Bont, E. S. J. M., Kamps, W. A., Morisaki, K., Bates, S. E., Scheffer, G. L., Scheper, R. J., Vellenga, E., & de Vries, E. G. E. (2003) · PubMed · Cited by 49
Wang, X., Wu, X., Wang, C., Zhang, W., Ouyang, Y., Yu, Y., & He, Z. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.033 · Cited by 47
Yamazaki, R., Nishiyama, Y., Furuta, T., Hatano, K., Igarashi, Y., Asakawa, N., Kodaira, H., Takahashi, H., Aiyama, R., Matsuzaki, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0874 · Cited by 47
Balabanov, S., Gontarewicz, A., Keller, G., Raddrizzani, L., Braig, M., Bosotti, R., Moll, J. K., Jost, E., Barett, C., Rohe, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019164 · Cited by 46
Semsei, Á. F., Erdelyi, D. J., Ungvári, I., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.12.009 · Cited by 46
Porro, A., Iraci, N., Soverini, S., Diolaiti, D., Gherardi, S., Terragna, C., Durante, S., Valli, E., Kalebic, T., Bernardoni, R., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0510 · Cited by 46
Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase
Takahashi, N., & Miura, M. (2011) · Pharmacology · doi:10.1159/000324900 · Cited by 45
Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells
Honorat, M., Mesnier, A., Pietro, A. D., Lin, V. C. L., Cohen, P. A., Dumontet, C., & Payen, L. F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.149 · Cited by 45
Detection of Hematopoietic Stem Cells by Flow Cytometry
Lin, K., & Goodell, M. A. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-385493-3.00002-4 · Cited by 44
Usuda, J., Tsunoda, Y., Ichinose, S., Ishizumi, T., Ohtani, K., Maehara, S., Ono, S., Tsutsui, H., Ohira, T., Okunaka, T., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.002 · Cited by 44
Zhao, L., Pan, Y., Yi, G., Wang, H., Jin, H., Tie, J., Xia, L., Zhang, Y., He, L., Yao, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.028068 · Cited by 43
Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins
Colabufo, N. A., Pagliarulo, V., Berardi, F., Contino, M., Inglese, C., Niso, M., Ancona, P., Albo, G., Pagliarulo, A., & Perrone, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.038 · Cited by 43
Detection and characterization of side population in Ewing’s sarcoma SK-ES-1 cells in vitro
Yang, M. H., Zhang, R., Yan, M., Ye, Z., Liang, W., & Luo, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.020 · Cited by 40
Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia
Lu, J., Ma, Y., Kong, N., Alipio, Z., Gao, C., Krause, D. S., Silberstein, L. E., & Chai, L. (2011) · Leukemia · doi:10.1038/leu.2011.65 · Cited by 40
Zong, Y., Zhou, S., Fatima, S., & Sorrentino, B. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606314200 · Cited by 36
Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco‐2 cells
Lemos, C., Kathmann, I., Giovannetti, E., Dekker, H., Scheffer, G. L., Calhau, C., Jansen, G., & Peters, G. J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23677 · Cited by 35
Usuda, J., Ohira, T., Suga, Y., Oikawa, T., Ichinose, S., Inoue, T., Ohtani, K., Maehara, S., Imai, K., Kubota, M., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.019 · Cited by 34
Biologic characteristics of the side population of human small cell lung cancer cell line H446
Wang, B., Yang, H., Huang, Y., et al. (2010) · 癌症:英文版 · doi:10.5732/cjc.009.10330 · Cited by 33
Effect of ABCG2 on cytotoxicity of platinum drugs: Interference of EGFP
Čečková, M., Vacková, Z., Radilová, H., Libra, A., Bunček, M., & Štaud, F. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2008.09.001 · Cited by 32
Cortez, M. A., Scrideli, C. A., Yunes, J. A., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22220 · Cited by 31
Lemos, C., Kathmann, I., Giovannetti, E., Beliën, J. A. M., Scheffer, G. L., Calhau, C., Jansen, G., & Peters, G. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0768 · Cited by 30
Borght, S. V., van Pelt, J. F., van Malenstein, H., Cassiman, D. M., Renard, M., Verslype, C., Libbrecht, L. J., & Roskams, T. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00381.x · Cited by 30
Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors
Kumamoto, H., & Ohki, K. (2009) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2009.00807.x · Cited by 30
Moreno‐Sanz, G., Barrera, B., Guijarro, A. I., D’Elia, I., Otero, J. A., Álvarez, A. I., Bandiera, T., Merino, G., & Piomelli, D. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.07.001 · Cited by 29
Ginguené, C., Champier, J., Maallem, S., Strazielle, N., Jouvet, A., Fèvre‐Montange, M., & Ghersi‐Egea, J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00389.x · Cited by 28
Vore, M. E., & Leggas, M. L. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.044289 · Cited by 28
Kang, K. W., Im, Y. B., Go, W. J., & Han, H.-K. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800116f · Cited by 28
Salphati, L., Lee, L. B., Pang, J., Plise, E. G., & Zhang, X. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034256 · Cited by 28
Immunohistochemical expression of multidrug resistance proteins in mature T/NK‐cell lymphomas
Sağlam, A., Hayran, M., & Üner, A. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.00974.x · Cited by 26
Biochemical rationale for the synergism of 5-fluorouracil and folinic acid.
Moran, R. G., & Keyomarsi, K. (1987) · PubMed · Cited by 26
Wang, F., Liang, Y.-J., Wu, X.-P., Chen, L., To, K. K. W., Dai, C.-L., Yan, Y., Wang, Y.-S., Tong, X.-Z., & Fu, L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.032 · Cited by 24
Vannini, I., Zoli, W., Tesei, A., et al. (2008) · Tumor Biology · doi:10.1159/000143400 · Cited by 23
Chu, T. S., Chen, J. S., Lopez, J. P., Pardo, F. S., Aguilera, J. A., & Ongkeko, W. M. (2008) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.134.9.979 · Cited by 21
Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines
Vannini, I., Zoli, W., Fabbri, F., Ulivi, P., Tesei, A., Carloni, S., Brigliadori, G., & Amadori, D. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833179bf · Cited by 13
Cited by
Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins
Yang, N. J., & Hinner, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2272-7_3 · Cited by 826
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Deng, Z. J., Morton, S. W., Ben-Akiva, E., Dreaden, E. C., Shopsowitz, K. E., & Hammond, P. T. (2013) · ACS Nano · doi:10.1021/nn4047925 · Cited by 516
Three-Dimensional Structures of Membrane Proteins from Genomic Sequencing
Hopf, T. A., Colwell, L. J., Sheridan, R., Rost, B., Sander, C., & Marks, D. S. (2012) · Cell · doi:10.1016/j.cell.2012.04.012 · Cited by 512
Metadata
- Authors
- Natarajan, K., Xie, Y., Baer, M. R., & Ross, D. D.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 83
- Issue
- 8
- Pages
- 1084-1103
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W1991953785
- Cited by
- 405
- References
- 237
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.